AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05325775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACER-801 50 mg BID
Description: 50 mg BID (twice daily)
Study NCT05325775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACER-801 100 mg BID
Description: 100 mg BID (twice daily)
Study NCT05325775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACER-801 200 mg BID
Description: 200 mg BID (twice daily)
Study NCT05325775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06519591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab, LM-302, S-1, paclitaxel
Description: Cadonilimab 10mg/kg, LM-302 2.0mg/kg intravenous (IV) infusion on day 1, paclitaxel 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
Study NCT04733547 — intervention group
Intervention type: PROCEDURE
Intervention: Placement of a central venous catheter
Description: The right internal jugular vein is located at the first rib level under ultrasound-guidance. Using an out-of-plane technique, a needle is introduced into the lumen of the vessel. The aspiration of blood into the syringe connected to the hub of the needle confirms the placement of the needle tip in the lumen. After the syringe is detached from the needle, a guidewire is advanced into the vessel lumen through the needle. A dilator is introduced over the guidewire and subsequently is removed. Then, a central venous catheter is introduced over the guidewire into the vessel lumen through the pathway expanded by the dilator. The catheter tip is placed in the superior vena cava by inserting the catheter as far as the distance between the edge of the right transverse process of the first thoracic vertebra and the carina, which is preoperatively measured on a posteroanterior chest radiograph.
Study NCT04733547 — intervention group
Intervention type: DEVICE
Intervention: Monitoring of central venous pressure
Description: Following the placement of a central venous catheter, a fluid-filled system for monitoring central venous pressure is connected to the proximal lumen of the catheter. The reference transducer is placed at the level of 4/5 of the anteroposterior diameter of the thorax.
Study NCT04733547 — intervention group
Intervention type: DRUG
Intervention: Furosemide-induced hypovolemia before graft procurement
Description: Patients fast from 10 pm the day before surgery. On the arrival at the operating room, an intravenous catheter for Plasmalyte infusion is placed into the right cephalic or basilic vein. The distal lumen of the central venous catheter is used for the infusion of 6% hydroxyethyl starch. Fluid requirements due to anesthesia, surgery, and no per os intake are not replaced by minimizing the administration of the fluids. Five minutes after the collection of the baseline data, 20 mg of furosemide is administered to promote diuresis for facilitating the venous outflow of the liver. An additional dose of furosemide 20 mg is given if the urine output is \<1 ml/kg within 30 minutes after the first dose. Unless the second dose of furosemide produces >1 ml/kg of urine within 30 minutes, 40 mg of furosemide is administered. In the absence of effective diuresis (1 ml/kg within 30 minutes after each dose), the use of furosemide is abandoned and the patients are excluded from the study.
Study NCT04733547 — intervention group
Intervention type: DRUG
Intervention: Replacement of fluid loss after graft procurement
Description: Immediately after the graft procurement, 500 ml of 6% hydroxyethyl starch are infused over 25 minutes. Afterward, Plasmalyte is infused at a rate of 10 ml/min until the end of surgery.
Study NCT04733547 — intervention group
Intervention type: DEVICE
Intervention: Monitoring of stroke volume variation
Description: Following anesthesia induction, the right radial artery is catheterized. The catheter is connected to the EV1000 monitor (Edwards Lifesciences, Irvine, CA) through the FloTrac transducer (Edwards Lifesciences). The transducer is level with the one for central venous pressure monitoring. Using pulse contour analysis without external calibration, the stroke volume for each heartbeat is measured. At a 20-second interval, stroke volume variation is calculated as (maximum stroke volume - minimum stroke volume)/mean stroke volume.
Study NCT06503445 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: education video
Description: the intervention group will watch the cardiac reahbiltation health education video.~the control group will watch the health educatopm video.
Study NCT06503445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education video
Description: the intervention group will watch the cardiac reahbiltation health education video.~the control group will watch the health educatopm video.
Study NCT05196763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Supplemental Nutrition Assistance Program-Education
Description: The Supplemental Nutrition Assistance Program-Education is federal nutrition education provided in all U.S. states to the SNAP-eligible population.
Study NCT05299385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilition treatment(e.g leaflet) educated by hospital
Description: Active Comparator: subjects who are trained in accordance with the conventional manual treatment of Respiratory rehabilitation in the clinical institution and taking care home-based management.~The manual contents~* method of the conventional rehabilitation treatment~* intensity for aerobic exercise and anaerobic exercise
Study NCT05299385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital treatment based on Respiratory Rehabilitation Software
Description: Experimental: subjects who use the software as a home-based Digital Respiratory Rehabilitation software~It is intended for subjects who are prescribed a respiratory rehabilitation exercise to improve their physical condition. The software also helps them to do self-rehabilitation exercise.
Study NCT06040320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Given at 1.8 mg/kg
Study NCT06040320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given at 375 mg/m\^2
Study NCT06040320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHP
Description: Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)
Study NCT05442619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venous blood collection
Description: Venous blood will be drawn from newborns.
Study NCT05442619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: Venous blood will be drawn from newborns.
Study NCT06023225 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pain
Description: Postoperative pain levels
Study NCT06023225 — intervention group
Intervention type: BEHAVIORAL
Intervention: Opioid use
Description: Postoperative opioid use
Study NCT05651919 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood test
Description: During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.
Study NCT05837741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard hypercaloric hyperproteic oral nutritional supplement
Description: Patients will receive nutritional support with Standard hypercaloric hyperproteic oral nutritional supplement
Study NCT05837741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
Description: Patients will receive nutritional support with Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
Study NCT05431296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom ONE Continuous Glucose Monitoring System
Description: The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.
Study NCT04849572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: * Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 1) will watch a 10 to 20 minute sleep hygiene video followed by a post-test questionnaire to confirm participation and understanding.~* Week 5: Arm 1 will again view the educational video at week 5~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 1 will continue re-education~* Week 11: Arm 1 continues education~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups.
Study NCT04849572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Sleep Education
Description: * Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 2) will be controls with no education.~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 2 will join in for video education along with post-test~* Week 11: Arm 2 will undergo reeducation with post-test for 20 mins~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups.
Study NCT04821583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone is orally administered.
Study NCT04821583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is orally administered.
Study NCT05649293 — intervention group
Intervention type: OTHER
Intervention: measure vitamin b6 in serum
Description: * Vitamin B6 levels can be determined by using Enzyme- linked Immuno-sorbent Assay Kit For vitamin B6 . or Chemiluminescence Immunoassays (CLIA) .~* Venous blood samples will be taken from each patient. Use a serum separator tube and allow samples to clot for 10-20 minutes at room temperature and then centrifuged for 20 minutes at speed of 2000-3000 rpm (round per minute).~* Remove supernatant, if precipitation appeared, Centrifuge again.~* Extract as soon as possible after Samples collection, and should be tested as soon as possible after the extraction.~* If not, samples must be stored in aliquot at -20°C (≤ 1 month) or -80°C (≤ 2 months) to avoid loss of bioactivity and contamination.~* Hemolyzed Sample will be avoided , as hemolysis will interfere with the results .
Study NCT04069052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.
Study NCT04069052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Room air (placebo) flowed into a mask and breathed in.
Study NCT04732754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + Theobroma cocoa (AETC)
Description: Daily consumption of 500mg cocoa in capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
Study NCT04732754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group (CG)
Description: Daily consumption of placebo capsules for 8 weeks
Study NCT04732754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise (AE)
Description: Daily consumption of placebo capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
Study NCT04732754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theobroma Cocoa (TC)
Description: Daily consumption of 500mg cocoa in capsules for 8 weeks.
Study NCT06421220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative injection of indocyanine green
Description: Submucosal injection of indocyanine green into the gastric mucosa prior to surgery， indocyanine green，25mg，powder，once
Study NCT05651919 — intervention group
Intervention type: BEHAVIORAL
Intervention: quality of life Questionnaire
Description: During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~* Level 1 is coded as a '1' (indicating no problem)~* Level 2 is coded as a '2' (indicating some problems)~* Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems.
Study NCT05087992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905711
Description: BI 905711
Study NCT05651919 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diet habits questionnaire
Description: During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits.~This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients.
Study NCT05087992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI
Study NCT06437938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement A: Wasabi leaf powder (product of BIOGENA GmbH & Co KG)
Description: To be taken according to the information in the study protocol/patient information leaflet.
Study NCT06437938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement B: Berberin Phytoactive Gold (product of BIOGENA GmbH & Co KG)
Description: To be taken according to the information in the study protocol/patient information leaflet.
Study NCT06437938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement C: DiaPhyt® Formula 3.0 (product of BIOGENA GmbH & Co KG)
Description: To be taken according to the information in the study protocol/patient information leaflet.
Study NCT06437938 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group 1: Placebo capsules corresponding to DiaPhyt® Formula 3.0/Berberin Phytoactive Gold
Description: To be taken according to the information in the study protocol/patient information leaflet.
Study NCT06437938 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group 2: Placebo powder corresponding to Wasabi leaf powder
Description: To be taken according to the information in the study protocol/patient information leaflet.
Study NCT04786600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signatera ctDNA assay
Description: Subjects will be tested with the Signatera ctDNA assay every 2 weeks.
Study NCT04786600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pre-specified sequence of FDA-approved drugs and drug combinations
Description: Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
Study NCT04786600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pre-specified sequence of FDA-approved drugs and drug combinations
Description: Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
Study NCT05019105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo
Study NCT05019105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALKS 1140
Description: Active oral dose of ALKS 1140
Study NCT06308770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants receive fatigue booklets from two charitable organisations providing information on fatigue, sleep, energy conservation, exercise and stress to help manage fatigue.
Study NCT06308770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 week FMP
Description: Participants attend 3 once weekly live online group interventions with a final intervention 8 weeks later.
Study NCT06308770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 7 week FMP
Description: Participants attend 6 once weekly live online group interventions with a final intervention 8 weeks later.
Study NCT05809531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor
Study NCT06772220 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid 1 MG
Description: Folic Acid 1mg per day
Study NCT06772220 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6 25 MG
Description: Vitamin B6, 25mg per day
Study NCT06772220 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12, 1,000 ug per day
Study NCT06772831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal by Distancing
Description: Reappraisal-by-distancing treatment. Patients meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique.
Study NCT06772831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Downregulate condition
Description: Patients either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
Study NCT06772818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral Tablet
Study NCT06772259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palm Stimulator
Description: The apparatus is 1.6 cm in diameter and 4 cm long. It has a cylindrical, non-slippery and easy-to-grasp structure for maximum contact with the palm
Study NCT06772259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon
Description: The cartoon was projected on a blank wall in the intervention room with a projection device. The cartoon was played in preparation for the PIK procedure and children were allowed to watch it until the procedure was completed.
Study NCT06772961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: In this study, the traditional acupoints Taiyuan (LU9) on the lung meridian and Hegu (LI4) on the large intestine meridian were selected. The lung and large intestine meridians are interconnected, so the combined application of Taiyuan and Hegu acupoints with TEAS can produce a synergistic effect. This combination enhances the replenishment of lung qi, promotes the flow of meridians, regulates qi, and disseminates lung functions. It can stimulate effective breathing in patients, thus positively influencing the improvement of their oxygen saturation levels.
Study NCT06772961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional care plan
Description: Conventional care plan
Study NCT05700123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-Office Hysteroscopy
Description: In-office hysteroscopic procedures were conducted using a 5mm continuous flow Office Hysteroscope using a vaginoscopic, no-touch, approach
Study NCT05700123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-Office Hysteroscopy
Description: In-office hysteroscopic procedures were conducted using a 5mm continuous flow Office Hysteroscope using a vaginoscopic, no-touch, approach
Study NCT05780385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasotracheal intubation
Description: patients requiring tracheal intubation receive nasotracheal intubation
Study NCT05780385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orotracheal intubation
Description: patients requiring tracheal intubation receive orotracheal intubation